Filing Flows › Twist Bioscience (TWST) › Q3 FY25
Twist Bioscience (TWST) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Aug 4, 2025
Twist Bioscience (TWST) reported revenue of $96.1M for the third quarter fiscal 2025 (Q3 FY25), +18% from a year earlier and +4% from the quarter before. Operating margin was -31.4%, net earnings $20.4M (21.2% of revenue).
Twist Bioscience, Q3 FY25: revenue $96.1M (+18% year over year), operating margin -31.4%, net earnings $20.4M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $96.1M | +4% | +18% |
| Operating profit | −$30.1M | — | — |
| Net earnings | $20.4M | — | — |
| Operating cash flow | −$1.4M | — | — |
What changed
Revenue was $96.1M in Q3 FY25, up 18% year over year and up 4% from the previous quarter. NGS tools was the largest line at 58% of revenue. NGS tools added $11.9M year over year (up 27%), 81% of the total change. DNA libraries declined 47%.
Operating costs exceeded revenue by $30.1M, an operating margin of -31.4%. Total costs fell 26% while revenue rose 18%. The fastest-growing cost line was SG&A (+12%). Net earnings were $20.4M. The effective tax rate was 0.9%. Non-operating items added $50.7M, 246% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.4M. Non-cash charges added back $6.1M of depreciation and amortization and $16.1M of share-based compensation. Working capital and other items used $43.9M. Capital expenditures of $9.2M exceeded it, leaving free cash flow of −$10.6M.
Questions
What was Twist Bioscience's revenue in the third quarter fiscal 2025?
Twist Bioscience (TWST) reported revenue of $96.1M for the third quarter fiscal 2025 (Q3 FY25), +18% from a year earlier and +4% from the quarter before.
Was Twist Bioscience profitable in the third quarter fiscal 2025?
Operating loss was $30.1M (-31.4% of revenue) and net earnings $20.4M.
Source: Twist Bioscience 10-Q on SEC EDGAR.